chlorzoxazone has been researched along with ns 1619 in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
| Cao, Y; Dreixler, JC; Houamed, KM; Roberts, MT; Roizen, JD | 1 |
| Alviña, K; Khodakhah, K | 1 |
3 other study(ies) available for chlorzoxazone and ns 1619
| Article | Year |
|---|---|
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
Modulation of recombinant small-conductance Ca(2+)-activated K(+) channels by the muscle relaxant chlorzoxazone and structurally related compounds.
Topics: Benzimidazoles; Calcium Channel Agonists; Cells, Cultured; Chlorzoxazone; Electrophysiology; Humans; Muscle Relaxants, Central; Potassium Channels; Potassium Channels, Calcium-Activated; Recombinant Proteins; Small-Conductance Calcium-Activated Potassium Channels; Structure-Activity Relationship; Zoxazolamine | 2001 |
KCa channels as therapeutic targets in episodic ataxia type-2.
Topics: Analysis of Variance; Animals; Benzimidazoles; Cerebellar Ataxia; Cerebellum; Chlorzoxazone; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesias; Humans; In Vitro Techniques; Intracellular Signaling Peptides and Proteins; Membrane Potentials; Mice; Mice, Inbred C57BL; Mice, Transgenic; Mutation; Potassium Channel Blockers; Potassium Channels; Purkinje Cells; Stress, Psychological | 2010 |